Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Change in Accured Expenses (2016 - 2024)

Sanara MedTech (SMTI) has disclosed Change in Accured Expenses for 14 consecutive years, with -$783390.0 as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Change in Accured Expenses rose 59.81% year-over-year to -$783390.0, compared with a TTM value of $1.1 million through Mar 2024, down 25.46%, and an annual FY2023 reading of -$81513.0, down 102.72% over the prior year.
  • Change in Accured Expenses was -$783390.0 for Q1 2024 at Sanara MedTech, down from $1.6 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.6 million in Q4 2023 and bottomed at -$1.9 million in Q1 2023.
  • Average Change in Accured Expenses over 5 years is $231970.4, with a median of $325788.0 recorded in 2020.
  • The sharpest move saw Change in Accured Expenses plummeted 380.24% in 2020, then soared 419.97% in 2022.
  • Year by year, Change in Accured Expenses stood at $524534.0 in 2020, then fell by 12.61% to $458405.0 in 2021, then soared by 222.35% to $1.5 million in 2022, then increased by 7.75% to $1.6 million in 2023, then crashed by 149.2% to -$783390.0 in 2024.
  • Business Quant data shows Change in Accured Expenses for SMTI at -$783390.0 in Q1 2024, $1.6 million in Q4 2023, and $185400.0 in Q3 2023.